Michael Henderson, M.D.
Michael joined BridgeBio to bring genetically targeted treatments to those patients with the highest unmet need. He is responsible for identifying and acquiring new technologies and playing a role in both the parent and subsidiary companies. Michael, who is currently serving as chief business officer and interim CEO for Origin Biosciences, has overseen the creation of 17 companies. He is a voting board member for 5 of BridgeBio’s subsidiary companies and cofounded PellePharm, one of BridgeBio’s portfolio companies, while in medical school. Prior to BridgeBio, Michael consulted for McKinsey & Company’s Silicon Valley Office where he served biotech clients across the U.S. and E.U. He holds an M.D. from Stanford University and received his B.A. from Harvard University.